Infection Prevention's Vital Role in CAR-T Cell Therapy
Researchers discovered that infections significantly contributed to non-relapse mortality among patients undergoing chimeric antigen receptor (CAR) T cell therapy ().
The team analyzed reports from 7604 patients across 18 clinical trials and 28 real world studies. Infections accounted for half of all reported non-relapse related deaths.
‘Preventing #infections is crucial after #CAR-T #celltherapy to mitigate the risk of non-relapse mortality, ’
Other cancers were the second most common driver at 7.8%.
Secondary Effects in CAR-T Cell Therapy
Cardiovascular or respiratory events were third, at 7.3%. Side effects specific to CAR-T cell therapy, such as cytokine release syndrome and neurotoxicity, played a minor role.Importantly, the researchers found non-relapse mortality to be associated with the underlying disease entity and certain CAR T-cell products, even when accounting for key study features.
Much attention has been paid to the risks associated with CAR-T cell therapy and managing CAR-T cell therapy specific side effects, such as cytokine release syndrome and neurotoxicity.
This study reveals that infections play a critical role in non-relapse related death and suggests a pressing need for comprehensive, evidence-based guidelines that inform infection prevention and management after CAR-T cell therapy.
The German Cancer Consortium, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), the Munich Clinician Scientist Program, the Bruno and Helene J�ster Foundation, the Bavarian Cancer Research Center, the National Institutes of Health/National Cancer Institute, and Arnold Ventures.
Reference:
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy - (https:www.nature.com/articles/s41591-024-03084-6)
Source: Eurekalert